Latest news with #DiabeticRetinopathy
Economic Times
2 days ago
- Health
- Economic Times
Retinal disorders a public health crisis, need immediate prioritisation, say experts
Synopsis Mission Vision, a public health initiative, has been launched in India to combat the escalating crisis of vision loss due to Diabetic Retinopathy. The initiative aims to increase awareness, improve screening and treatment access, and integrate eye care into routine diabetes management. ET Spotlight Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi) and Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai) A staggering public health crisis is unfolding in India, the world's diabetes capital, leading to a surge in irreversible vision loss from conditions such as Diabetic Retinopathy (DR). This disease damages the retina, the eye's crucial 'reel', and often strikes people in their most productive years. Lack of awareness remains a primary concern, with nearly 90% of diabetic patients having never had a retinal exam and seeking help only after permanent damage has occurred. The problem is worsened by a severe shortage of specialists and the failure to integrate eye care into routine diabetes management. To combat this escalating threat, Mission Vision, a public health initiative by The Vitreo Retinal Society of India (VRSI) and The Times of India, with support from Roche, was launched in July 2025. Under the Mission Vision initiative, a VRSI-led multistakeholder task force called the VIEW (Vision Improvement Experts Working) Council is putting together a comprehensive roadmap to tackle DR and make retinal health a national to address gaps in awareness, screening, diagnosis and treatment, infrastructure, and capacity-building were discussed. When implemented, these potential solutions could preserve the sight of millions who are at risk following key actionables emerged from the discussion: A clarion call for nationwide awareness A nationwide awareness campaign, similar to the Pulse Polio programme, is essential to address preventable blindness so that people can take action before it is too late. Emphasising the need for a collaborative approach, Dr R. Kim, President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai, said, 'There are many people doing a great job of reaching patients, but it is happening in pockets. We must integrate the entire network: primary care physicians, diabetologists, optometrists, and chemists to ensure that every patient with DR is identified early on and taken care of. It is about starting a national conversation where every patient asks for an eye exam. We cannot afford to lose another person's vision to silence.' To achieve this, the following were suggested: Multi-stakeholders through different channels to maximise awareness Implement government mandates to ensure systemic integration Sensitise and leverage the existing healthcare ecosystem, including community (e.g. ASHA workers) Collaborate with trusted NGOs for nationwide scale, trust, and reach Push for mandatory DR screening Policy reform is crucial to make DR screening a fundamental right for every diabetic patient by 2030. Dr Manisha Agarwal, General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi, said, 'Currently, Ayushman Bharat includes DR screening in 12 states but only upon submission of an OCT photograph, which restricts its use by physicians who may not have an OCT machine. Expansion of DR screening to all states and the implementation of scalable screening models can improve DR detection significantly.' The experts advocated for making annual DR screening a standard part of diabetes care. To facilitate this, screening must be linked to a patient's digital health ID or Aadhaar for effective tracking and follow-up. While screening and diagnosis are the start of the patient journey, the inclusion of intravitreal injections in Ayushman Bharat can go a long way towards improving access to treatment for DR, said most experts. Speaking on the need for coordinated action, Roche Pharma's Rajwinder (Rajji) Mehdwan said, 'The question is not if we can eliminate preventable vision loss, but how soon we act to build a future where sight is accessible for all. Roche is committed to bringing its global healthcare ecosystem shaping expertise to make Mission Vision a reality.' Building a robust screening-to-treatment pathway A robust referral system is needed to ensure patients diagnosed with DR receive proper, timely treatment. Dr Vishali Gupta, Chief of Retina and Uvea Services at PGI, Chandigarh, said, 'One of the biggest hurdles for timely treatment is in getting patients to the right retina specialist, as the referral pathways in these cases are fragmented. There is a need for a holistic national referral pathway so that we all know what a patient's journey looks like and ensure every patient gets access to specialised retinal care that they need.' An accountable, pyramid model and significant upskilling of the healthcare workforce were suggested through the following actions: Implement uniform postgraduate training so all ophthalmologists can confidently perform dilated retinal exams. Train ASHA workers for doorstep identification, and skill nurses and primary care physicians to administer prescribed intravitreal injections. Train technicians to use low-cost, AI-enabled devices for grassroots screening, sending images to central hubs for specialist diagnosis. Driving systemic change through policy reformExperts recommended following comprehensive policy changes to manage DR, urging the government to recognise its severe economic impact, particularly on young, productive individuals: Integrate DR screening into the national NCD programme via existing health and wellness centres. Expand Ayushman Bharat's DR screening nationwide, remove the mandatory OCT photo for reimbursement, and add coverage for intravitreal injections so that the best treatment options are made available to patients Replicate successful state models nationwide, such as Andhra Pradesh's camera distribution to diabetologists and Kerala's Nayan Amritham programme. This comprehensive, multi-sectoral approach, driven by collective will and clear policy, is critical to transforming the landscape of retinal health in India. The ambitious journey to safeguard the vision of millions has begun with Mission Vision, aiming for a future where sight is accessible for all. Disclaimer: The views and opinions expressed in the story are independent professional judgments of the doctors/experts, and TIL does not take any responsibility for the accuracy of their views. This should not be considered a substitute for medical advice. Please consult your treating physician for more details. This article has been produced by Times Internet's Spotlight team. (This article is generated and published by ET Spotlight team. You can get in touch with them on etspotlight@
Time of India
2 days ago
- Health
- Time of India
Retinal disorders a public health crisis, need immediate prioritisation, say experts
Advertorial Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Popular in Healthcare/Biotech 1. Managing diabetes in a country obsessed with quick fixes: A scientific perspective Multi-stakeholders through different channels to maximise awareness Implement government mandates to ensure systemic integration Sensitise and leverage the existing healthcare ecosystem, including community (e.g. ASHA workers) Collaborate with trusted NGOs for nationwide scale, trust, and reach Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi) [L to R] Dr. Vinod Agarwal (Professor of Vitreo Retina Services, AIIMS, New Delhi); Ms. Rajwinder (Rajji) Mehdwan (CEO and MD, Roche Pharma); Dr. Muna Bhende (Director Vitreo Retinal Services, Sankara Nethralaya, Chennai); Dr. Rajeev R Pappuru (Consultant Ophthalmologist, Vice Chair, L V Prasad Eye Institute, Hyderabad); Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi); and Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai) [L to R] Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi) and Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai); Dr. Chaitra Jayadev (Senior Consultant- Vitreoretina Services, Narayana Nethralaya, Bengaluru); Dr. Vishali Gupta (Chief of Retina and Uvea Services at Post Graduate Institute (PGI) of Medical Education and Research, Chandigarh) Implement uniform postgraduate training so all ophthalmologists can confidently perform dilated retinal exams. Train ASHA workers for doorstep identification, and skill nurses and primary care physicians to administer prescribed intravitreal injections. Train technicians to use low-cost, AI-enabled devices for grassroots screening, sending images to central hubs for specialist diagnosis. Tired of too many ads? Remove Ads Integrate DR screening into the national NCD programme via existing health and wellness centres. Expand Ayushman Bharat's DR screening nationwide, remove the mandatory OCT photo for reimbursement, and add coverage for intravitreal injections so that the best treatment options are made available to patients Replicate successful state models nationwide, such as Andhra Pradesh's camera distribution to diabetologists and Kerala's Nayan Amritham programme. (This article is generated and published by ET Spotlight team. You can get in touch with them on etspotlight@ A staggering public health crisis is unfolding in India, the world's diabetes capital, leading to a surge in irreversible vision loss from conditions such as Diabetic Retinopathy (DR).This disease damages the retina, the eye's crucial 'reel', and often strikes people in their most productive years. Lack of awareness remains a primary concern, with nearly 90% of diabetic patients having never had a retinal exam and seeking help only after permanent damage has occurred. The problem is worsened by a severe shortage of specialists and the failure to integrate eye care into routine diabetes combat this escalating threat, Mission Vision, a public health initiative by The Vitreo Retinal Society of India (VRSI) and The Times of India, with support from Roche, was launched in July 2025. Under the Mission Vision initiative, a VRSI-led multistakeholder task force called the VIEW (Vision Improvement Experts Working) Council is putting together a comprehensive roadmap to tackle DR and make retinal health a national to address gaps in awareness, screening, diagnosis and treatment, infrastructure, and capacity-building were discussed. When implemented, these potential solutions could preserve the sight of millions who are at risk following key actionables emerged from the discussion:A nationwide awareness campaign, similar to the Pulse Polio programme, is essential to address preventable blindness so that people can take action before it is too the need for a collaborative approach, Dr R. Kim, President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai, said, 'There are many people doing a great job of reaching patients, but it is happening in pockets. We must integrate the entire network: primary care physicians, diabetologists, optometrists, and chemists to ensure that every patient with DR is identified early on and taken care of. It is about starting a national conversation where every patient asks for an eye exam. We cannot afford to lose another person's vision to silence.'Policy reform is crucial to make DR screening a fundamental right for every diabetic patient by 2030. Dr Manisha Agarwal, General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi, said, 'Currently, Ayushman Bharat includes DR screening in 12 states but only upon submission of an OCT photograph, which restricts its use by physicians who may not have an OCT machine. Expansion of DR screening to all states and the implementation of scalable screening models can improve DR detection significantly.'The experts advocated for making annual DR screening a standard part of diabetes care. To facilitate this, screening must be linked to a patient's digital health ID or Aadhaar for effective tracking and follow-up. While screening and diagnosis are the start of the patient journey, the inclusion of intravitreal injections in Ayushman Bharat can go a long way towards improving access to treatment for DR, said most on the need for coordinated action, Roche Pharma's Rajwinder (Rajji) Mehdwan said, 'The question is not if we can eliminate preventable vision loss, but how soon we act to build a future where sight is accessible for all. Roche is committed to bringing its global healthcare ecosystem shaping expertise to make Mission Vision a reality.'A robust referral system is needed to ensure patients diagnosed with DR receive proper, timely treatment. Dr Vishali Gupta, Chief of Retina and Uvea Services at PGI, Chandigarh, said, 'One of the biggest hurdles for timely treatment is in getting patients to the right retina specialist, as the referral pathways in these cases are fragmented. There is a need for a holistic national referral pathway so that we all know what a patient's journey looks like and ensure every patient gets access to specialised retinal care that they need.'An accountable, pyramid model and significant upskilling of the healthcare workforce were suggested through the following actions:Experts recommended following comprehensive policy changes to manage DR, urging the government to recognise its severe economic impact, particularly on young, productive individuals:This comprehensive, multi-sectoral approach, driven by collective will and clear policy, is critical to transforming the landscape of retinal health in India. The ambitious journey to safeguard the vision of millions has begun with Mission Vision, aiming for a future where sight is accessible for all.
Time of India
22-07-2025
- Health
- Time of India
Vision loss due to Diabetic Retinopathy: A national crisis
As India grapples with an escalating diabetes crisis, with 101 million 1 diagnosed and 136 million with pre-diabetes, the country is faced with an urgent but unrecognised public health threat from Diabetic Retinopathy (DR), Diabetic Macular Edema (DME) and Vision-Threatening Diabetic Retinopathy (VTDR). A staggering 16.9% of people with diabetes suffer from DR, and 3.6% from VTDR 2 and face irreversible blindness. It strikes people in their most productive years, severely impacting their quality of life and creating profound economic and social ramifications. As India aims to become a developed economy by 2047 (Viksit Bharat), improving citizens' quality of life is a key government agenda. Retinal diseases, often overlooked, demand the same urgency and national focus that transformed cataract care in the country. In response to this urgent challenge, Mission Vision has been launched to elevate retinal health to the forefront of India's public health agenda. Mission Vision: A confluence of expertise Mission Vision, a public health initiative by The Vitreo Retinal Society of India (VRSI) and Times of India, supported by Roche, has been launched to tackle preventable blindness and improve retinal health in India. Under Mission Vision, the VIEW Council, a multi-stakeholder task force of retina experts, ophthalmology societies, policymakers, and industry partners has been formed to focus on reducing the burden of avoidable blindness due to DR. The inaugural meeting saw strong participation from the VRSI leadership, alongside other leading experts. The Council pledged to drive multi-stakeholder action, build awareness, advocate for early screening, and better access to treatment across India. [L to R] Dr. Vinod Aggarwal (Professor of Vitreo Retina Services, AIIMS, New Delhi); Dr. Muna Bhende (Director Vitreo Retinal Services, Sankara Nethralaya, Chennai); and Dr. Rajeev R Pappuru (Consultant Ophthalmologist, Vice Chair, L V Prasad Eye Institute, Hyderabad) Founding members of the VIEW council Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai) Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi) Dr. Vishali Gupta (Chief of Retina and Uvea Services at Post Graduate Institute (PGI) of Medical Education and Research, Chandigarh) Dr. Muna Bhende (Director Vitreo Retinal Services, Sankara Nethralaya , Chennai) Dr. Vinod Agarwal (Professor of Vitreo Retina Services, AIIMS, New Delhi) Dr. Rajeev R Pappuru (Consultant Ophthalmologist, Vice Chair, L V Prasad Eye Institute, Hyderabad) Dr. Chaitra Jayadev (Senior Consultant- Vitreoretina Services, Narayana Nethralaya, Bengaluru) Dr. Partha Biswas (President, AIOS and Medical Director at Netralayam and Trenetralaya , Kolkata) Dr. Ajay Aurora (Executive Director Vitreoretina Consultant , Vision Plus Eye Centre, Noida) Ms. Rajwinder (Rajji) Mehdwan (CEO and MD, Roche Pharma) [L to R] Ms. Rajwinder (Rajji) Mehdwan (CEO and MD, Roche Pharma); Dr. Muna Bhende (Director Vitreo Retinal Services, Sankara Nethralaya, Chennai); Dr. Rajeev R Pappuru (Consultant Ophthalmologist, Vice Chair, L V Prasad Eye Institute, Hyderabad); Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi); and Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai) The experts acknowledged the tremendous efforts taken by the government to combat blindness secondary to cataract; however, the tide of retinal disorders due to diabetes is a growing and urgent problem. A recurring theme was the critical need for a massive, nationwide awareness campaign. Nearly nine out of 10 patients with diabetes had never had a retinal examination 3 , showing the enormity of the problem. Driving focus on retinal disorders and making annual retinal examinations a national priority will ensure this growing disease burden is addressed. [L to R] Dr. Manisha Agarwal (General Secretary, VRSI and HOD, Vitreo Retina Dept, Dr Shroff's Charity Eye Hospital, New Delhi) and Dr. R Kim (President, VRSI and Chief Medical Officer, Aravind Eye Hospital, Madurai); Dr. Chaitra Jayadev (Senior Consultant- Vitreoretina Services, Narayana Nethralaya, Bengaluru); Dr. Vishali Gupta (Chief of Retina and Uvea Services at Post Graduate Institute (PGI) of Medical Education and Research, Chandigarh); and Dr. Partha Biswas (President, AIOS and Medical Director at Netralayam and Trenetralaya, Kolkata) Dr. R Kim emphasised the need for a collaborative approach, stating, 'Several stakeholders must be involved to increase awareness. Not only the patients with diabetes, but even primary care physicians, diabetologists, chemists, and optometrists must be made aware of the dangers of retinal disorders like DR. It is about starting a national conversation where every patient asks for an eye exam. We cannot afford to lose another person's vision to silence.' This sentiment was echoed with a call for making screening ubiquitous. Dr. Manisha Agarwal drew a powerful analogy for its ideal accessibility, 'Diabetes is silently stealing the sight of millions across urban and rural India, often without any warning. The real tragedy is that blindness due to DR is preventable. DR screening should be as accessible as the availability of a weighing machine at railway stations. On the other hand, the inclusion of intravitreal injections in Ayushman Bharat , with its need being assessed by OCT, can go a long way towards improving access to treatment.' Experts also highlighted the need to leverage government schemes. Dr. Vishali Gupta pointed out, 'Ayushman Bharat has been a phenomenal effort to ensure that treatment reaches the most vulnerable. NGOs and strategic public-private partnerships can also help in improving awareness and DR screening at the grassroots level. However, a lot needs to be done towards upskilling the ophthalmologists to screen and evaluate patients with retinal disorders effectively.' Creative strategies for awareness such as reaching out to schools and organizations with a large sedentary population were also discussed. Dr. Muna Bhende suggested a two-pronged approach for different demographics. 'School children can become your primary influencers, and sensitize their parents to the dangers of blindness due to DR. Also, awareness programmes can leverage the trust that NGOs have built with the local population to ensure the message reaches every corner of India.' Setting a clear, ambitious goal was seen as crucial. Dr. Rajeev R Pappuru articulated a powerful vision for the future. 'By 2030, no diabetic should go without an eye check-up, including a retinal screening. From the first diagnosis of diabetes to annual follow-ups, DR screening should become an integral part of diabetes care, with access at the patient's doorstep.' To achieve all of this, patient empowerment is key. Dr. Vinod Agarwal said, 'Our growth over the past few decades has been due to the demand in services. Raise awareness to the level that the patients demand DR screening and we can then offer it as a service. That will help in widespread adoption of screening and also help in mandating the availability of fundus cameras at all centres. Also, the inclusion of intravitreal injections in Ayushman Bharat can go a long way towards improving access to treatment for DR.' Currently, Ayushman Bharat includes DR screening in 12 states but only upon submission of an OCT photograph, which restricts its use by physicians who may not have an OCT machine. In some states, the government has supplied physicians and diabetologists with non-mydriatic fundus cameras which help in detection of DR. Expansion of DR screening under Ayushman Bharat to all states and the implementation of such scalable screening models can improve DR detection significantly, the experts opined. Dr. Chaitra Jayadev emphasised, 'Every physician who encounters a patient with diabetes must urge them to go for retinal screening. The outstanding success with the pulse polio program shows us that widespread awareness campaigns can yield results. Our country's technological prowess can be leveraged to develop low-cost screening devices that can help us reach every patient. Linking the Aadhar ID/digital health IDs to medical records can also help clinicians track the patient's progress and ensure adequate follow-up.' Alongside awareness, building capacity is also important. With only 3500 retinal specialists available, striking a balance by finding innovative avenues to upskill the workforce is essential. Dr. Partha Biswas stressed, 'Academic enhancement and capacity building should go hand-in-hand with increasing awareness. Training postgraduate students in fundus screening and enhancing their ability to detect these disorders can help improve access to care.' Addressing the infrastructure gap is another critical piece of the puzzle. Dr. Ajay Aurora provided a stark reality check. 'There are 806 districts in India but only 50% have district hospitals, and only two-thirds of those have ophthalmology services. Putting a hub-and-spoke model in place so that patients are referred to adequately equipped care centres is essential.' Speaking on the need for urgent action, Roche Pharma's Rajwinder (Rajji) Mehdwan said, 'To millions suffering from retinal diseases, the gift of vision should be a guarantee, a right, supported by the very best of our science, our policy, and our collective will. The question is not if we can eliminate preventable vision loss, but how soon we act to build a future where sight is accessible for all. Vision health is not a luxury but a necessity for every individual to live a fulfilling life. By making it a national priority, we can ensure a world where everyone has the opportunity to see clearly and experience life to its fullest. Roche is committed to bringing its global healthcare ecosystem shaping expertise to make Mission Vision a reality.' [L to R] Dr. Indu Bhushan (Former CEO, National Health Authority & Ayushman Bharat) and Dr. Rajni Kant Srivastava, ICMR- Chair for Disease Elimination The discussion coalesced around the need for concrete policy action with contributions from eminent policymakers. Dr. Indu Bhushan (Former CEO, National Health Authority & Ayushman Bharat), drawing from his extensive experience, noted, 'Retina health is closely tied to the twin silent epidemics of Diabetes and Hypertension in India. Policy change can happen if there is enough evidence. A policy document that explains the scale of the problem, its economic and social impact, existing gaps in the ophthalmology space, and how they can be plugged can help put things in perspective.' Providing an update on current government efforts, Dr. K Madan Gopal (Advisor, Public Health Administration, NHSRC, Ministry of Health & Family Welfare) said, 'We have defined norms through the Indian Public Health Standards for all levels of care. Furthermore, at our 1,70,000 Ayushman Arogya Mandirs, we are already equipping our Community Health Officers for the basic screening of eye disorders, including the use of an ophthalmoscope.' Talking about best practices that can be replicated, Dr. Rajni Kant Srivastava , ICMR- Chair for Disease Elimination said, 'Though India is a land of vast disparities, states like Kerala have prioritized eye health. For instance, the Nayan Amritham initiative was a successful and scalable programme in which ASHA workers identified diabetic patients for retinopathy screening using handheld non-mydriatic cameras. The images were sent to a central hub for evaluation and treatment advice. Telemedicine can also help in ensuring care reaches remote areas.' The VIEW Council charter: A roadmap to help India see better The culmination of these deliberations was a comprehensive charter, a clear and actionable roadmap designed to make retinal screening a fundamental right in India and aiming to decrease VTDR to less than 1%. Mission Vision will focus on driving large-scale public awareness about DR, integrate retinal screening with existing NCD screening programmes, design protocols for every patient to undergo retinal screening, build capacity for widespread screening and diagnosis, and ensure advanced treatment options, like intravitreal injections, are made available through programmes like Ayushman Bharat. The VIEW Council's inaugural meeting marks a decisive and powerful step towards safeguarding the vision of millions. With a clear charter, the journey to make retinal health a national priority has officially begun. References -
Express Tribune
24-06-2025
- Health
- Express Tribune
Experts warn of rising diabetes-linked blindness
Al-Shifa Trust (AST) has raised serious concerns over the rising threat of Diabetic Retinopathy (DR) in Pakistan, linking it to the country's alarming surge in diabetes cases — now reportedly the highest in the world. Speaking to media on Tuesday, Dr Nadeem Qureshi, Head of the Retina Department at Al-Shifa Trust Eye Hospital, warned that the increasing diabetes prevalence is fuelling a parallel spike in vision-threatening complications, including diabetic retinopathy, cataracts, and glaucoma. "Prolonged uncontrolled blood sugar damages the retinal blood vessels and, if left untreated, can lead to irreversible vision loss," he said. He emphasized that early detection and routine screening are critical in preventing vision impairment.
Globe and Mail
12-03-2025
- Business
- Globe and Mail
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Diabetic Retinopathy Pipeline Insight ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook Key Takeaways from the Diabetic Retinopathy Pipeline Report In March 2025:- Vantage Biosciences Ltd announced a study to evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR). In March 2025:- Invirsa Inc. announced a phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 1]. In March 2025:- Incepta Pharmaceuticals Ltd conducted a study to to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection. In March 2025:- EyePoint Pharmaceuticals Inc. announced a study of Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME). DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment. The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment Diabetic Retinopathy Emerging Drugs Profile Tarcocimab tedromer: Kodiak Sciences Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy. OTT166: Ocuterra Therapeutics Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. APX3330: Apexian Pharmaceuticals APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy. OTX-TKI: Ocular Therapeutix OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy. The Diabetic Retinopathy Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment. Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs Diabetic Retinopathy Companies Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives Scope of the Diabetic Retinopathy Pipeline Report Coverage- Global Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective Table of Content Introduction Executive Summary Diabetic Retinopathy: Overview Pipeline Therapeutics Therapeutic Assessment Diabetic Retinopathy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) KSI-301: Kodiak Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) RGX 314: Regenxbio Inc Drug profiles in the detailed report….. Early Stage Products (Phase I) OTX-TKI: Ocular Therapeutix Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetic Retinopathy Key Companies Diabetic Retinopathy Key Products Diabetic Retinopathy- Unmet Needs Diabetic Retinopathy- Market Drivers and Barriers Diabetic Retinopathy- Future Perspectives and Conclusion Diabetic Retinopathy Analyst Views Diabetic Retinopathy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
